Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 1,79 € (+1391,67 %). La mediana es de 1,79 € (+1391,67 %).
| Comprar |
8 |
| Mantener |
4 |
| Vender |
1 |
Noticias Ir al feed de noticias
Accuray reports mixed Q4 results: revenue weaker, stock under pressure
Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » Más en de.investing.com
Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence
Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » Más en de.investing.com
Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs
Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 88,43 M | 18,28 % |
| Beneficio bruto | 31,14 M | 5,84 % |
| Beneficio neto | -1,7 M | 278,50 % |
| EBITDA | 8,08 M | 20,56 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 14,85 M € |
Número de acciones | 119,44 M |
Máximo/mínimo de 52 semanas | 1,31 € - 0,11 € |
| Dividendos | No |
Beta | 1,42 |
Ratio P/E | -0,35 |
Ratio PEG | 0,00 |
Ratio P/B | 0,41 |
Ratio P/S | 0,04 |
Perfil de la empresa
Accuray Incorporated diseña, desarrolla, fabrica y vende sistemas de radiocirugía y de radioterapia para el tratamiento de tumores en América, Europa, Oriente Medio, India, África, Japón, China y el resto de la región de Asia-Pacífico. Ofrece el sistema CyberKnife, un sistema robótico de radiocirugía estereotáctica y de radioterapia corporal estereotáctica utilizado para el tratamiento de diversos tipos de cáncer y tumores en el cuerpo, como los de próstata, pulmón, cerebro, columna vertebral, hígado, páncreas y riñón. La compañía también proporciona el sistema TomoTherapy, incluido el sistema Radixact, que consiste en un sistema integrado de radioterapia diseñado para el tratamiento de una variedad de tipos de cáncer. Además, ofrece servicios de atención al cliente posteriores al contrato, instalación, formación y otros servicios profesionales. La compañía comercializa sus productos principalmente de forma directa a los clientes, entre ellos hospitales y centros de tratamiento independientes, a través de su organización de ventas, así como a clientes mediante agentes de ventas y organizaciones de compra en grupo en Estados Unidos; y a clientes de forma directa y a través de distribuidores y agentes de ventas a nivel internacional. Accuray Incorporated se fundó en 1990 y tiene su sede en Sunnyvale, California.
| Nombre | Accuray |
| CEO | Stephen R. LaNeve |
| Sede | Madison,
wi Estados Unidos |
| Sitio web | |
| Sector | Consumo discrecional |
| Industria | Bienes duraderos del hogar |
| Salida a bolsa | 08/02/2007 |
| Empleados | 809 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | ARAY |
London Stock Exchange | 0H8I.L |
Frankfurt | XEJ.F |
Düsseldorf | XEJ.DU |
London | 0H8I.L |
SIX | XEJ.SW |
München | XEJ.MU |